Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.

Abstract

To determine whether microcrystalline hydroxyapatite compound (MCHC) could reduce bone loss or its consequences in patients with chronic active hepatitis (CAH) on corticosteroid therapy, a controlled trial was conducted in 36 such patients over a period of 2 years. Both skeletal symptoms (back pain) and fractures were uncommon during the trial period but both showed non-significant differences in favour of the MCHC group and biochemical investigations were suggestive of a reduction in parathyroid over-activity. Continued reduction in bone mineral content of the radius (photon absorptiometry) was halted in those receiving MCHC and iliac crest bone biopsy showed a non-significant increase in trabecular bone volume. The fall in iliac crest cortical plate thickness was significantly less (P less than 0.025) in the MCHC group and the results overall were consistent with a beneficial effect from MCHC in corticosteroid-induced osteoporosis.

Statistics

0200400'96'98'00'02'04'06'08'10'12'14'16
Citations per Year

151 Citations

Semantic Scholar estimates that this publication has 151 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Stellon1985MicrocrystallineHC, title={Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.}, author={A. J. Stellon and A. Geraint Davies and Amy Webb and Roger Williams}, journal={Postgraduate medical journal}, year={1985}, volume={61 719}, pages={791-6} }